Keyword: Umicore

News

Umicore and VW Arm Establish European Battery JV

29.09.2022 -

Belgian chemical producer and recycler Umicore and PowerCo, the newly created battery company of the Volkswagen (VW) group, have officially founded their envisioned joint...

News

Umicore and Volkswagen in EV Battery Materials JV

10.12.2021 -

Belgian chemicals and recycling company Umicore is teaming up with German carmaker Volkswagen in a joint venture to produce cathode materials for VW’s battery cell...

News

Umicore Acquires YPhos Ligand Technology from Bochum University

09.12.2020 -

Umicore‘s business unit Precious Metals Chemistry is further expanding its cross-coupling catalyst portfolio by acquiring Ruhr University Bochum’s YPhos ligands and...

Strategy & Management

Experts Statements: Christophe Le Ret, Umicore

05.09.2019 - The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...

Strategy & Management

The Pharma CDMO Challenge

05.09.2019 - The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...

News

Umicore Expands Metathesis Chemistry and Cross-coupling Catalysis Portfolio

15.07.2019 - Umicore‘s business unit Precious Metals Chemistry has signed an agreement with Evonik to take over the German specialty chemicals company’s intellectual property in the field of...

News

Umicore Adds Yale’s Hazari Precatalysts to Expand its Cross-Coupling Technology Portfolio

30.04.2019 - The business unit Precious Metals Chemistry of Umicore is expanding its cross-coupling catalyst portfolio with Hazari’s palladium based precatalysts, a technology licensed from...

Plant Construction & Process Technology

M&A in Pharma and CRO/CMO Industry

19.09.2018 - Recently, the pharmaceutical contract development and manufacturing organization (CDMO) industry has been extremely active in M&A, as is the pharma and generics industry itself...